TerminatedNot Applicable

UVA1 Light for Scleroderma and Similar Conditions

Stopped: inactivity

United States23 participantsStarted 1997-01

Plain-language summary

The purpose of this investigation is to evaluate the effectiveness of high-dose UVA1 irradiation in the treatment of fibrosing conditions of the skin, e.g., keloid (a thick scar from growth of fibrous tissue), scleroderma (deposits of fibrous tissue in the skin) and acne keloidalis nuchae (keloids on the back of the neck or hairline) old burn scars, granuloma annulare or other similar skin conditions. This UVA1 dosing schedule has been used successfully in Germany for various skin diseases, such as the above mentioned scleroderma.

Who can participate

Age range10 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age: 10-80 years * Clinical diagnosis of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare, and other related conditions associated with altered dermal matrix. * No disease states or physical conditions which would impair evaluation of the test site. * Willing and able to receive UVA1 as directed in the protocol, make evaluation visits, and follow protocol restrictions. * Signed, written, witnessed, informed consent form. * Must live within driving distance of Ann Arbor, Michigan. Exclusion Criteria: * History of photosensitivity. * Pregnant or nursing women. * Systemic therapy for the fibrosing skin condition within 30 days prior to study enrollment. * Involved in an investigational study within the previous 4 weeks.

What they're measuring

Measurement of plaque thickness, increase in mobility, plaque hardness

Timeframe: 16 weeks

Trial details

NCT IDNCT00476697

SponsorUniversity of Michigan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2003-07

View on ClinicalTrials.gov More Keloid trials